Diego Malon Gimenez
@diegomalon.bsky.social
Medical oncologist at Dr. George L. Dumont University Hospital (breast, melanoma, lung) Moncton (NB) trained at Princess Margaret CC Toronto.
Reposted by Diego Malon Gimenez
1. Recent #FDA approvals:
a). #NATALEE: Adj #Ribociclib in HR+ Stg IIA - III, 400mg 3wks on, 1wk off for 3yrs. 3yr iDFS 90.7% vs 87.6, 3.1% absolute iDFS
b). #INAVO120: Inavolisib + Fulvestrant + Palbo vs Palbo/Fulvestrant HR+ mBC. PFS 15.0 vs 7.3mos (HR 0.43)
2/5
a). #NATALEE: Adj #Ribociclib in HR+ Stg IIA - III, 400mg 3wks on, 1wk off for 3yrs. 3yr iDFS 90.7% vs 87.6, 3.1% absolute iDFS
b). #INAVO120: Inavolisib + Fulvestrant + Palbo vs Palbo/Fulvestrant HR+ mBC. PFS 15.0 vs 7.3mos (HR 0.43)
2/5
December 11, 2024 at 2:26 AM
1. Recent #FDA approvals:
a). #NATALEE: Adj #Ribociclib in HR+ Stg IIA - III, 400mg 3wks on, 1wk off for 3yrs. 3yr iDFS 90.7% vs 87.6, 3.1% absolute iDFS
b). #INAVO120: Inavolisib + Fulvestrant + Palbo vs Palbo/Fulvestrant HR+ mBC. PFS 15.0 vs 7.3mos (HR 0.43)
2/5
a). #NATALEE: Adj #Ribociclib in HR+ Stg IIA - III, 400mg 3wks on, 1wk off for 3yrs. 3yr iDFS 90.7% vs 87.6, 3.1% absolute iDFS
b). #INAVO120: Inavolisib + Fulvestrant + Palbo vs Palbo/Fulvestrant HR+ mBC. PFS 15.0 vs 7.3mos (HR 0.43)
2/5
Reposted by Diego Malon Gimenez
4. #KN522: current SoC PeriOp IO + neoAdj Chemo and then Adj IO for high risk TNBC.
- This remains the current standard of care. As of now, there are no specific markers available in clinical practice to predict IO benefit in these patients.
5/5
- This remains the current standard of care. As of now, there are no specific markers available in clinical practice to predict IO benefit in these patients.
5/5
December 11, 2024 at 2:26 AM
4. #KN522: current SoC PeriOp IO + neoAdj Chemo and then Adj IO for high risk TNBC.
- This remains the current standard of care. As of now, there are no specific markers available in clinical practice to predict IO benefit in these patients.
5/5
- This remains the current standard of care. As of now, there are no specific markers available in clinical practice to predict IO benefit in these patients.
5/5
Reposted by Diego Malon Gimenez
3. #DB06: . DestinyBreast06: Ph III, TDXd vs chemo in endocrine resistant HR+ HER2 low and HER2-ultralow
- Improved PFS regardless of time to progression on CDK4/6i or tumor burden
- PFS2 better w/ TDXd
- In what line will you use this??
4/5
- Improved PFS regardless of time to progression on CDK4/6i or tumor burden
- PFS2 better w/ TDXd
- In what line will you use this??
4/5
December 11, 2024 at 2:26 AM
3. #DB06: . DestinyBreast06: Ph III, TDXd vs chemo in endocrine resistant HR+ HER2 low and HER2-ultralow
- Improved PFS regardless of time to progression on CDK4/6i or tumor burden
- PFS2 better w/ TDXd
- In what line will you use this??
4/5
- Improved PFS regardless of time to progression on CDK4/6i or tumor burden
- PFS2 better w/ TDXd
- In what line will you use this??
4/5
Reposted by Diego Malon Gimenez
2. #PADMA: Ph III, HR+ metastatic breast cancer, chemo vs ET + Palbociclib.
- #SABCS22 in #RightChoice study, we knew CDK4/6i upfront is better.
- Time to treatment failure and PFS better in PADMA. CDK4/6i remain 1L SoC for these pts
3/5
- #SABCS22 in #RightChoice study, we knew CDK4/6i upfront is better.
- Time to treatment failure and PFS better in PADMA. CDK4/6i remain 1L SoC for these pts
3/5
December 11, 2024 at 2:26 AM
2. #PADMA: Ph III, HR+ metastatic breast cancer, chemo vs ET + Palbociclib.
- #SABCS22 in #RightChoice study, we knew CDK4/6i upfront is better.
- Time to treatment failure and PFS better in PADMA. CDK4/6i remain 1L SoC for these pts
3/5
- #SABCS22 in #RightChoice study, we knew CDK4/6i upfront is better.
- Time to treatment failure and PFS better in PADMA. CDK4/6i remain 1L SoC for these pts
3/5